Junyu Zhang
Building 13, No. 130, Dongan Road
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Correction: Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Journal: Oncogene
Published: February 06, 2026
IKBKE regulates renal cell carcinoma progression and sunitinib resistance through the RRM2-AKT pathway.
Journal: International journal of biological sciences
Published: August 22, 2024
Erratum to "Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion" [Eur. Urol. 75(5) (2019) 752-763].
Journal: European urology
Published: September 25, 2023
Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Journal: Molecular carcinogenesis
Published: December 20, 2022
Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: May 07, 2021
GPR160 is a potential biomarker associated with prostate cancer.
Journal: Signal transduction and targeted therapy
Published: December 14, 2020
Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer.
Journal: World journal of urology
Published: November 23, 2018
CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: January 18, 2018
Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer.
Journal: Oncoimmunology
Published: December 15, 2017
Last Updated: 09/26/2026